Mutations in Two Genes Encoding Different Subunits of a Receptor Signaling Complex Result in an Identical Disease Phenotype
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL), also known as "Nasu-Hakola disease," is a globally distributed recessively inherited disease leading to death during the 5th decade of life and is characterized by early-onset progressive dementia and bone cysts. Elsewhere, we have identified PLOSL mutations in TYROBP (DAP12), which codes for a membrane receptor component in natural-killer and myeloid cells, and also have identified genetic heterogeneity in PLOSL, with some patients carrying no mutations in TYROBP. Here we complete the molecular pathology of PLOSL by identifying TREM2 as the second PLOSL gene. TREM2 forms a receptor signaling complex with TYROBP and triggers activation of the immune responses in macrophages and dendritic cells. Patients with PLOSL have no defects in cell-mediated immunity, suggesting a remarkable capacity of the human immune system to compensate for the inactive TYROBP-mediated activation pathway. Our data imply that the TYROBP-mediated signaling pathway plays a significant role in human brain and bone tissue and provide an interesting example of how mutations in two different subunits of a multisubunit receptor complex result in an identical human disease phenotype.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Homozygous loss-of-function mutations in TREM2 or DAP12 genes cause Nasu–Hakola disease (NHD), a rare genetic disorder characterized by fatal presenile dementia and bone cysts [38, 39].”
From TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis (2020) · cites this paper as [39]
In the citing paper
“TYROBP is a transmembrane adaptor protein for TREM2, SIRPβ1, and CR3 receptors, which are known to be involved in AD pathogenesis [90–92].”
From Sex-specific DNA methylation differences in Alzheimer’s disease pathology (2021) · cites this paper as [92]
In the citing paper
“Homozygous Q33X, Y38C and T66M variants have been identified in patients with Nasu-Hakola disease [44, 47, 95].”
From TREM2/PLCγ2 signalling in immune cells: function, structural insight, and potential therapeutic modulation (2021) · cites this paper as [95]
In the citing paper
“A number of mutations in PLCG2 (about 75%), that have been previously implicated in various inflammatory diseases [92–102], actually map to the autoinhibitory interface on the PLCγ2 model structure and can be considered as pathogenic (Fig. 2c)”
From TREM2/PLCγ2 signalling in immune cells: function, structural insight, and potential therapeutic modulation (2021) · cites this paper as [95]
In the citing paper
“Even more rare loss-of-function mutations of TREM2 or DAP12 cause a form of recessively inherited presenile dementia, called Nasu-Hakola disease (126, 127).”
From Microglia Function in the Central Nervous System During Health and Neurodegeneration (2017) · cites this paper as [126]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Bouchon, A., Dietrich, J., & Colonna, M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.10.4991 · Cited by 1,284 · cited 4×
“2001a), whereas TREM2 is expressed on macrophages and monocyte-derived dendritic cells, suggesting that TREM2 plays a role in chronic, rather than in acute, inflammation (Bouchon et al. 2000).”
BackgroundInfluentialTREM-1 amplifies inflammation and is a crucial mediator of septic shock
Bouchon, A., Facchetti, F., Weigand, M. A., & Colonna, M. (2001) · Nature · doi:10.1038/35074114 · Cited by 1,090 · cited 2×
“TREM1 is strongly up-regulated in cells that mediate acute inflammatory responses to bacterial infection (i.e., neutrophils and monocytes) (Bouchon et al. 2001a), whereas TREM2 is expressed on macrophages and monocyte-derived dendritic cells, suggesting that TREM2 plays a role in chronic, rather…”
BackgroundImmunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells
Lanier, L. L., Corliss, B. C., Wu, J., Leong, C., & Phillips, J. H. (1998) · Nature · doi:10.1038/35642 · Cited by 904 · cited 5×
“This has been shown to disrupt the association with (McVicar et al. 1998; Bakker et al. 1999), as well as the cell-surface expression of, TYROBP (Lanier et al. 1998b; Smith et al. 1998).”
BackgroundInfluentialVitale, M., Bottino, C., Sivori, S., Sanseverino, L., Castriconi, R., Marcenaro, E., Augugliaro, R., Moretta, L., & Moretta, A. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.12.2065 · Cited by 748 · cited 1×
“1) (Vitale et al. 1998), MDL1 (chromosome 7q33) (Bakker et al. 1999), CD94 (chromosome 12p13.”
Association of DAP12 with Activating CD94/NKG2C NK Cell Receptors
Lanier, L. L., Corliss, B., Wu, J., & Phillips, J. H. (1998) · Immunity · doi:10.1016/s1074-7613(00)80574-9 · Cited by 559 · cited 5×
“This has been shown to disrupt the association with (McVicar et al. 1998; Bakker et al. 1999), as well as the cell-surface expression of, TYROBP (Lanier et al. 1998b; Smith et al. 1998).”
BackgroundInfluentialLoss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts
Paloneva, J., Kestilä, M., Wu, J., Salminen, A., Böhling, T., Ruotsalainen, V., Hakola, P., Bakker, A. B. H., Phillips, J. H., Pekkarinen, P., et al. (2000) · Nature Genetics · doi:10.1038/77153 · Cited by 460 · cited 6×
“Interestingly, patients with PLOSL who are homozygous for mutations in either TREM2 or TYROBP display identical CNS and bone manifestations (table 2)—and no immunological symptoms (Paloneva et al. 2000).”
BackgroundInfluentialSelf-citationBouchon, A., Hernández-Munain, C., Cella, M., & Colonna, M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.8.1111 · Cited by 460 · cited 2×
“TREM1 is strongly up-regulated in cells that mediate acute inflammatory responses to bacterial infection (i.e., neutrophils and monocytes) (Bouchon et al. 2001a), whereas TREM2 is expressed on macrophages and monocyte-derived dendritic cells, suggesting that TREM2 plays a role in chronic, rather…”
BackgroundLy-49D and Ly-49H associate with mouse DAP12 and form activating receptors.
Smith, K. M., Wu, J., Bakker, A. B. H., Phillips, J. H., & Lanier, L. L. (1998) · PubMed · Cited by 277
Cutting Edge: Ly-49D and Ly-49H Associate with Mouse DAP12 and Form Activating Receptors
Smith, K. M., Wu, J., Bakker, A. B. H., Phillips, J. H., & Lanier, L. L. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.1.7 · Cited by 249 · cited 1×
“This has been shown to disrupt the association with (McVicar et al. 1998; Bakker et al. 1999), as well as the cell-surface expression of, TYROBP (Lanier et al. 1998b; Smith et al. 1998).”
BackgroundMutations in PATCHED-1, the receptor for SONIC HEDGEHOG, are associated with holoprosencephaly
Ming, J. E., Kaupas, M. E., Roessler, E., Brunner, H. G., Golabi, M., Tekin, M., Stratton, R. F., Sujansky, E., Bale, S. J., & Muenke, M. (2002) · Human Genetics · doi:10.1007/s00439-002-0695-5 · Cited by 244
Research works printed but not linked: 1
- Tranebjærg, 2000, Polycystic lipomembranous osteodysplasia, Tidsskr Nor Laegeforen, 120, 3196
Cited by
Items 301–400 of 694
Understanding microglial diversity and implications for neuronal function in health and disease
De Schepper, S., Crowley, G., & Hong, S. (2021) · Developmental Neurobiology · doi:10.1002/dneu.22777 · Cited by 57
Knapskog, A.-B., Henjum, K., Idland, A.-V., Eldholm, R. S., Persson, K., Saltvedt, I., Watne, L. O., Engedal, K., & Nilsson, L. N. G. (2020) · Scientific Reports · doi:10.1038/s41598-020-72878-8 · Cited by 49
Role of TREM2 in Alzheimer’s Disease: A Long Road Ahead
Kulkarni, B., Kumar, D., Martins, N. A., & Sellamuthu, S. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02477-9 · Cited by 54
“Microglial cells are the cells of CNS, mostly responsible for managing immune function.”
BackgroundInfluentialPenney, J., Ralvenius, W. T., Loon, A., Cerit, O., Dileep, V., Milo, B., Pao, P., Woolf, H., & Tsai, L. (2024) · Glia · doi:10.1002/glia.24485 · Cited by 52
“…TYROBP were identified as causative mutations for polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL), an aggressive early onset disease characterized by bone cysts, demyelination, neurodegeneration, and dementia (Errichiello et al., 2019; Paloneva et al., 2002).”
BackgroundCarbajosa, G., Malki, K., Lawless, N., Wang, H., Ryder, J. W., Wozniak, E., Wood, K., Mein, C. A., Dobson, R. J. B., Collier, D. A., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.04.019 · Cited by 49
Ohgidani, M., Kato, T. A., & Kanba, S. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00184 · Cited by 48
“NHD is a very rare autosomal recessive disease, and the responsible two genes, which are expressed in microglia in the brain, are DNAX-activation protein of 12 kDA (DAP12) and triggering receptor expressed on myeloid cells 2 (TREM2; Paloneva et al., 2000, 2002).”
BackgroundThe Enigmatic Function of TREM-2 in Osteoclastogenesis
Colonna, M., Turnbull, I. R., & Klesney‐Tait, J. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-72009-8_13 · Cited by 56
“In these culture conditions, blood monocyte derived from TREM-2- or DAP12-deficient patients were incapable of fusing into multinucleated osteoclasts endowed with bone resorptive activity (Table 1) (Cella, Buonsanti, Strader, et al. 2003; Paloneva, Mandelin, Kiialainen, et al. 2003 ).”
BackgroundIntracranial hypotension after chiropractic manipulation of the cervical spine
Beck, J., Raabe, A., Seifert, V., & Dettmann, E. (2003) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.6.821 · Cited by 52
Association of APOE With Primary Open-Angle Glaucoma Suggests a Protective Effect for APOE ε4
Margeta, M. A., Letcher, S. M., Igo, R. P., Cooke Bailey, J. N., Pasquale, L. R., Haines, J. L., Butovsky, O., Wiggs, J. L., & for the NEIGHBORHOOD consortium (2020) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.61.8.3 · Cited by 51
The therapeutic potential of TREM2 in cancer
Wolf, E. M., Fingleton, B., & Hasty, A. H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.984193 · Cited by 52
Rohn, T. T. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/860959 · Cited by 49
“Interestingly, it is only individuals that are heterozygous for TREM2 that are at risk for AD: homozygous, autosomal recessive mutations for TREM2 result in The Nasu-Hakola disease in some individuals characterized by bone cysts and dementia [75], while resulting in fronttemporal dementia without bone disease in other…”
BackgroundDeming, Y., Li, Z., Benitez, B. A., & Cruchaga, C. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1486823 · Cited by 48
Compartmentalization of ITAM and integrin signaling by adapter molecules
Bezman, N., & Koretzky, G. A. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00541.x · Cited by 59
Central pontine myelinolysis temporally related to hypophosphataemia
Michell, A. W., Burn, D. J., & Reading, P. J. (2003) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.6.820 · Cited by 51
DAP12 signaling: from immune cells to bone modeling and brain myelination
Colonna, M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17745 · Cited by 50
“In addition, TREM-2 transcripts have been detected in human osteoclasts (13), human brain (13), and murine microglial cells (14).”
BackgroundInfluentialFrom Common to Rare Variants: The Genetic Component of Alzheimer Disease
Nicolas, G., Charbonnier, C., & Campion, D. (2016) · Human Heredity · doi:10.1159/000452256 · Cited by 51
Kuil, L. E., Oosterhof, N., Geurts, S. N., van der Linde, H. C., Meijering, E. H. W., & van Ham, T. J. (2019) · Disease Models & Mechanisms · doi:10.1242/dmm.037762 · Cited by 53
Lopez‐Atalaya, J. P., Askew, K. E., Sierra, A., & Gomez‐Nicola, D. (2018) · Developmental Neurobiology · doi:10.1002/dneu.22545 · Cited by 49
“In humans, recessive mutations in DAP-12 or its associated cellsurface receptor TREM-2 cause Nasu-Hakola Disease, which is characterized by frontal dementia and bone cysts (Paloneva et al., 2000, 2002).”
BackgroundER-to-Golgi Trafficking and Its Implication in Neurological Diseases
Wang, B., Stanford, K. R., & Kundu, M. (2020) · Cells · doi:10.3390/cells9020408 · Cited by 51
“, Nasu–Hakola disease, also known as polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy) [102,103].”
BackgroundMcFarland, K. N., & Chakrabarty, P. (2022) · Neurotherapeutics · doi:10.1007/s13311-021-01179-3 · Cited by 48
“These patients suffer from the Nasu–Hakola disease (polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy or PLOSL), which is also associated with early dementia but is primarily characterized by bone cysts [222].”
BackgroundMicroglia and Brain Disorders: The Role of Vitamin D and Its Receptor
Mirarchi, A., Albi, E., Beccari, T., & Arcuri, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241511892 · Cited by 54
“One prominent characteristic observed in the brains of NHD patients is the widespread activation of microglia, predominantly in the frontal and temporal areas [73].”
BackgroundInfluentialGenetic architecture of common non-Alzheimer’s disease dementias
Guerreiro, R. J., Gibbons, E., Tábuas‐Pereira, M., Kun‐Rodrigues, C., Cordeiro, G., & Brás, J. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104946 · Cited by 51
Novel Targets for Alzheimer's Disease: A View Beyond Amyloid
Ray, W. J., & Buggia-Prevot, V. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-052919-120219 · Cited by 43
Frontobasal gray matter loss is associated with the TREM2 p.R47H variant
Luis, E. O., Ortega-Cubero, S., Lamet, I., Razquin, C., Cruchaga, C., Benitez, B. A., Lorenzo, E., Irigoyen, J., Pastor, M. A., & Pastor, P. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.06.007 · Cited by 47
“Leukoaraiosis is a common feature of NHD caused by TREM2 recessive mutations (Paloneva et al., 2002).”
InfluentialTREM2 is down-regulated by HSV1 in microglia and involved in antiviral defense in the brain
Fruhwürth, S., Reinert, L. S., Öberg, C., Sakr, M., Henricsson, M., Zetterberg, H., & Paludan, S. R. (2023) · Science Advances · doi:10.1126/sciadv.adf5808 · Cited by 40
“In humans, loss-of-function mutations of TREM2 or DAP12 result in Nasu-Hakola disease, a serious disorder characterized by presenile dementia and bone cysts (21, 22).”
BackgroundDifferential Modulation of TREM2 Protein during Postnatal Brain Development in Mice
Chertoff, M., Shrivastava, K., Gonzalez, B., Acarin, L., & Giménez-Llort, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072083 · Cited by 47
“lipomembranous osteodysplasia with sclerosing leukoencephalopathy; PLOSL), characterized by an early onset dementia associated with bone cysts [36,37].”
BackgroundFrom beta amyloid to altered proteostasis in Alzheimer’s disease
Bruni, A. C., Bernardi, L., & Gabelli, C. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101126 · Cited by 53
Control of Innate Immunity by Sialic Acids in the Nervous Tissue
Liao, H., Klaus, C., & Neumann, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155494 · Cited by 48
“Moreover, loss-of-function mutations of either TREM2 or DAP12 are related to the development of a presenile dementia with bone cysts, a rare hereditary autosomal-recessive disease called Nasu–Hakola disease or polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy [31,32].”
BackgroundDisease susceptibility genes for autism
Bespalova, I. N., & Buxbaum, J. D. (2003) · Annals of Medicine · doi:10.1080/07853890310005966 · Cited by 44
Harnessing Immunoproteostasis to Treat Neurodegenerative Disorders
Golde, T. E. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.027 · Cited by 45
TREM2 analysis and increased risk of Alzheimer's disease
Finelli, D., Rollinson, S. J., Harris, J., Jones, M. S., Richardson, A. M. T., Gerhard, A., Snowden, J. S., Mann, D. M. A., & Pickering-Brown, S. M. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.08.001 · Cited by 47
“TREM2 is located on chromosome 6 and encodes the triggering receptor expressed on myeloid cells 2 protein (Paloneva et al., 2002).”
BackgroundInfluentialInvolvement of FcR in signal transduction of osteoclast-associated receptor (OSCAR)
Ishikawa, S. (2004) · International Immunology · doi:10.1093/intimm/dxh103 · Cited by 45
Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers
Ashton, N. J., Suárez-Calvet, M., Heslegrave, A., Hye, A., Razquin, C., Pastor, P., Sanchez-Valle, R., Molinuevo, J. L., Visser, P. J., Blennow, K., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0545-5 · Cited by 46
Microglia control small vessel calcification via TREM2
Zarb, Y., Sridhar, S., Nassiri, S., Utz, S. G., Schaffenrath, J., Maheshwari, U., Rushing, E. J., Nilsson, K. P. R., Delorenzi, M., Colonna, M., et al. (2021) · Science Advances · doi:10.1126/sciadv.abc4898 · Cited by 43
Zhu, C., Herrmann, U. S., Li, B., Abakumova, I., Moos, R., Schwarz, P., Rushing, E. J., Colonna, M., & Aguzzi, A. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.02.019 · Cited by 44
“Loss-of-function mutations in TREM2 occur in patients suffering from Nasu-Hakola disease, which is characterized by bone cysts and early-onset, progressive dementia (Paloneva et al., 2002).”
BackgroundTherapeutic Effect of Modulating TREM-1 via Anti-inflammation and Autophagy in Parkinson’s Disease
Feng, C., Chen, N., Sung, C., Kuo, H., Yang, S., Chen, C., Hung, H.-C., Chen, B., Wen, Z., & Chen, W.-F. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00769 · Cited by 45
Microglia: The Missing Link to Decipher and Therapeutically Control MS Progression?
Geladaris, A., Häusler, D., & Weber, M. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073461 · Cited by 47
“Loss of function due to the mutation in TREM2 or DAP12 genes causes Nasu–Hakola disease, a rare genetic disorder, which is characterized by demyelination and microglial activation [107].”
BackgroundRegulation of microglial survival and proliferation in health and diseases
Ulland, T. K., Wang, Y., & Colonna, M. (2015) · Seminars in Immunology · doi:10.1016/j.smim.2016.03.011 · Cited by 43
“In the CNS, TREM2 expression is limited to microglia [23,26,30,31].”
BackgroundChen, D., Wang, C., Chen, X., Li, J., Chen, S., Li, Y., Ma, F., Li, T., Zou, M., Li, X., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.ads6111 · Cited by 43
Mutation analysis of the MS4A and TREM gene clusters in a case-control Alzheimer's disease data set
Ghani, M., Sato, C., Kakhki, E. G., Gibbs, J. R., Traynor, B. J., George‐Hyslop, P. S., & Rogaeva, E. A. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.03.009 · Cited by 45
Dean, H. B., Roberson, E. D., & Song, Y. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01252 · Cited by 42
“NasuHakola disease–associated coding mutations tend to be grossly inactivating, usually by early truncations—such as E14X (3), Q33X (4), W44X (2), or W78X (2)—or frameshifts—such as G90VfsX99 or A105RfsX84 (5).”
BackgroundNeuroimaging in genetic frontotemporal dementia and amyotrophic lateral sclerosis
Häkkinen, S., Chu, S. A., & Lee, S. E. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105063 · Cited by 43
Neuroinflammation — using big data to inform clinical practice
Dendrou, C. A., McVean, G., & Fugger, L. H. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.171 · Cited by 48
“Similarly, genetic variation in the Triggering receptor expressed on myeloid cells 2 ( TREM2 ) gene, which is involved in microglial activity, is associated with AD 37-41 and other neurological disorders, including Nasu–Hakola disease 42 , frontotemporal dementia 43,44 , PD 44 and ALS 45 .”
BackgroundKusanovic, J. P., Romero, R. J., Chaiworapongsa, T., Mittal, P., Mazaki‐Tovi, S., Vaisbuch, E., Erez, O., Gotsch, F., Than, N. G., Edwin, S. S., et al. (2009) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767050903009248 · Cited by 48
“In contrast to TREM-1, TREM-2 is expressed in immature monocyte-derived dendritic cells as well as in osteoclasts [55], brain [56] and microglia [57], orchestrating the differentiation of myeloid precursors towards mature dendritic cells, osteoclast, microglia and possibly oligodendrocytes.”
ResultSirkis, D. W., Aparicio, R. E., & Schekman, R. (2017) · Molecular Biology of the Cell · doi:10.1091/mbc.e17-06-0423 · Cited by 41
“To further investigate and expand on these findings, we began by generating the six known missense mutations (Y38C, T66M, D86V, V126G, D134G, and K186N) implicated in NHD or early-onset FTD lacking the bone phenotype (Paloneva et al., 2002; Klünemann et al., 2005; Guerreiro et al., 2013a,c; Le Ber et al., 2014).”
BackgroundAcute anterior radiculitis associated with West Nile virus infection
Park, M., Hui, J. S., & Bartt, R. E. (2003) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.6.823 · Cited by 42
Alzheimer’s disease: rare variants with large effect sizes
Del-Aguila, J. L., Koboldt, D. C., Black, K., Chasse, R., Norton, J., Wilson, R. K., & Cruchaga, C. (2015) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2015.07.008 · Cited by 41
“Current Opinion in Genetics & Development 2015, 33:49–55 onset frontotemporal-like (FTD-like) dementia and bone involvement [27,28].”
TREM2 mRNA Expression in Leukocytes Is Increased in Alzheimer’s Disease and Schizophrenia
Mori, Y., Yoshino, Y., Ochi, S., Yamazaki, K., Kawabe, K., Abe, M., Kitano, T., Ozaki, Y., Yoshida, T., Numata, S., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0136835 · Cited by 41
“It is reported that TYROBP expression is normal in the brain of NHD individuals with the TREM2 mutation [2] and that TREM2mRNA extracted from leukocytes is severely reduced in NHD individuals with this mutation [19].”
BackgroundAlzheimer’s Disease Biomarkers Revisited From the Amyloid Cascade Hypothesis Standpoint
Alawode, D. O. T., Fox, N. C., Zetterberg, H., & Heslegrave, A. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.837390 · Cited by 45
Das, M., Mao, W., Voskobiynyk, Y., Necula, D., Lew, I., Petersen, C., Zahn, A., Yu, G.-Q., Yu, X., Smith, N., et al. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106263 · Cited by 41
“Homozygous mutations that inactivate TREM2 cause Nasu-Hakola disease, which combines early-onset dementia with epilepsy and other abnormalities (Paloneva et al., 2002; Bianchin et al., 2004; Kaneko et al., 2010; Nakamagoe et al., 2011; Jay et al., 2017).”
SH3BP2 is an activator of NFAT activity and osteoclastogenesis
Lietman, S. A., Yin, L., & Levine, M. A. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.04.080 · Cited by 46
“[19–21] Previous studies in T cells have shown that overexpression of SH3BP2 activates transcription of a hybrid reporter gene in which luciferase expression is regulated by a promoter region containing the NFAT binding sequence from the interleukin 2 (IL-2) gene.”
BackgroundA case of possible autoimmune bilateral vestibulopathy treated with steroids
Schüler, O. G., Strupp, M., Arbusow, V., & Brandt, T. (2003) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.6.825 · Cited by 44
“The disease is characterised by genetic heterogeneity: mutations in two genes (TYROBP and TREM2) encoding different subunits of a membrane receptor complex in natural killer and myeloid cells have been associated with the disease.”
Fan, Z., Su, D., Li, Z. C., Sun, S., & Ge, Z. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03313-2 · Cited by 40
Roles of TREM2 in Alzheimer’s disease
Qi, X., Zhu, K., Ke, W., Wang, J., Mao, S., & Chen, G. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00515-3 · Cited by 42
“Conversely, complete TREM2 KO may better recapitulate the pathological hallmarks of NHD [373].”
Alzheimer’s disease pathological lesions activate the spleen tyrosine kinase
Schweig, J. E., Yao, H., Beaulieu-Abdelahad, D., Ait-Ghezala, G., Mouzon, B., Crawford, F., Mullan, M., & Paris, D. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0472-2 · Cited by 40
“Interestingly, loss-of-function mutations in the DAP12 or TREM2 genes cause a rare autosomal recessive disorder called Nasu-Hakola disease (NHD) whereas heterozygous carriers of these mutations show an elevated risk to develop AD [27].”
A c sf1rb mutation uncouples two waves of microglia development in zebrafish
Ferrero, G., Miserocchi, M., Ruggiero, E. D., & Wittamer, V. (2020) · Development · doi:10.1242/dev.194241 · Cited by 46
Edwin, T. H., Henjum, K., Nilsson, L. N. G., Watne, L. O., Persson, K., Eldholm, R. S., Saltvedt, I., Halaas, N. B., Selbæk, G., Engedal, K., et al. (2020) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12128 · Cited by 33
Hemmi, H., Zaidi, N., Wang, B., de Matos, I. G., Fiorese, C. J., Lubkin, A., Zbytnuik, L. D., Suda, K., Zhang, K., Noda, M., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1102541 · Cited by 43
Li, R., Wang, X., & He, P. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.9778 · Cited by 39
Feiten, A. F., Dahm, K., Schlepckow, K., van Lengerich, B., Suh, J. H., Reifschneider, A., Wefers, B., Bartos, L. M., Wind-Mark, K., de Weerd, L., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68706-8 · Cited by 39
Irfan, M., Evonuk, K. S., & DeSilva, T. M. (2022) · The FEBS Journal · doi:10.1111/febs.16190 · Cited by 39
Macrophages regulate gastrointestinal motility through complement component 1q
Pendse, M., Selle, H. D., Vo, N., Quinn, G. M., Dende, C., Li, Y., Salinas, C. N., Srinivasan, T., Propheter, D. C., Crofts, A. A., et al. (2023) · eLife · doi:10.7554/elife.78558 · Cited by 39
“Third, C1q-expressing intestinal macrophages showed elevated expression of Arginase 1, CD169, and TREM2 (triggering receptor expressed on myeloid cells 2)(Figure 4D), which are enriched on macrophages with known neuromodulatory functions (Colonna, 2003; Paloneva et al., 2002; Ural et al., 2020).”
BackgroundAlzheimer's disease risk alleles in TREM2 illuminate innate immunity in Alzheimer's disease
Golde, T. E., Streit, W. J., & Chakrabarty, P. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt178 · Cited by 38
“Homozygous, loss of function mutations in both TREM2 and DAP12 are known causes of polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL), which is also known as Nasu Hakola disease [24-27].”
Carter, C. J. (2013) · Pathogens and Disease · doi:10.1111/2049-632x.12077 · Cited by 38
“The TYROBP/TREM2 complex triggers activation of the immune responses in macrophages, microglia and dendritic cells (Paloneva et al., 2002; Zhang et al., 2013).”
BackgroundMontalbetti, L., Ratti, M. T., Greco, B., APRILE, C., Moglia, A., & Soragna, D. (2005) · PubMed · Cited by 42
Sekiya, M., Wang, M., Fujisaki, N., Sakakibara, Y., Quan, X., Ehrlich, M. E., De Jager, P. L., Bennett, D. A., Schadt, E. E., Gandy, S., et al. (2018) · Genome Medicine · doi:10.1186/s13073-018-0530-9 · Cited by 38
“TREM2 variants were originally identified as causative mutations in patients with Nasu-Hakola disease [66].”
BackgroundFamilial trisomy 6p in mother and daughter
Savarese, M., Grandone, A., Perone, L., Blanco, F. D. V., Luca, G. D., Fruscio, G. D., Fogu, G., Piluso, G., Perrone, L., del Giudice, E. M., et al. (2013) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.35928 · Cited by 38
“…Mb, excludes TFAP2B and contains 163 RefSeq genes, including 139 genes listed in OMIM and 51(CUL7 [Huber et al., 2005], POLR1C [Dauwerse et al., 2011], RSPH9 [Castleman et al., 2009], RUNX2 [Zhou et al., 1999], TREM2 [Paloneva et al., 2002] for example) associated with a pathological phenotype.”
BackgroundInfluentialZhang, H., Lü, S., Tao, J., Chen, R., Li, Y., Sun, Z., & Qian, W. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3740 · Cited by 40
Merck, E., de Saint-Vis, B., Scuiller, M., Gaillard, C., Caux, C., Trinchieri, G., & Bates, E. E. M. (2005) · Blood · doi:10.1182/blood-2004-07-2809 · Cited by 41
Microglial tissue surveillance: The never‐resting gardener in the developing and adult CNS
Petry, P., Oschwald, A., & Kierdorf, K. (2023) · European Journal of Immunology · doi:10.1002/eji.202250232 · Cited by 41
Giannoccaro, M. P., Bartoletti‐Stella, A., Piras, S., Pession, A., Massis, P. D., Oppi, F., Maserati, M. S., Pasini, E., Baiardi, S., Avoni, P., et al. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8540-x · Cited by 42
Genetic underpinnings in Alzheimer’s disease – a review
Moustafa, A. A., Hassan, M., Hewedi, D. H., Hewedi, I. H., Garami, J. K., Alashwal, H., Zaki, N., Seo, S., Cutsuridis, V., Angulo, S. L., et al. (2017) · Reviews in the Neurosciences · doi:10.1515/revneuro-2017-0036 · Cited by 40
“Another gene, TREM2, also causes the autosomal recessive form of dementia-like symptoms after homozygous mutations (Paloneva et al., 2002).”
BackgroundSokolova, D., Childs, T., & Hong, S. Y. (2021) · Faculty Reviews · doi:10.12703/r/10-19 · Cited by 39
Microglia in Neurodegenerative Events—An Initiator or a Significant Other?
Harry, G. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115818 · Cited by 40
Immune Semaphorins: Increasing Members and Their Diverse Roles
Kikutani, H., Suzuki, K., & Kumanogoh, A. (2007) · Advances in immunology · doi:10.1016/s0065-2776(06)93003-x · Cited by 41
Belloli, S., Pannese, M., Buonsanti, C., Maiorino, C., Di Grigoli, G., Carpinelli, A., Monterisi, C., Moresco, R. M., & Panina-Bordignon, P. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.01.010 · Cited by 34
Microglial TREM2 in amyotrophic lateral sclerosis
Xie, M., Zhao, S., Bosco, D. B., Nguyen, A. T., & Wu, L. (2021) · Developmental Neurobiology · doi:10.1002/dneu.22864 · Cited by 36
“Inactivating mutations of TREM2 were first identified within Nasu-Hakola disease (NHD), a neurodegenerative disease manifesting early-onset progressive dementia and bone cysts (Klunemann et al., 2005; Paloneva et al., 2002).”
BackgroundThe Primary Microglial Leukodystrophies: A Review
Ferrer, I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116341 · Cited by 40
PET imaging of microglia in Alzheimer's disease using copper-64 labeled TREM2 antibodies
Shojaei, M., Schaefer, R., Schlepckow, K., Kunze, L. H., Struebing, F. L., Brunner, B., Willem, M., Bartos, L. M., Feiten, A., Palumbo, G., et al. (2024) · Theranostics · doi:10.7150/thno.97149 · Cited by 36
“The critical function of TREM2 is highlighted by the homozygous loss-of-function mutation that results in Nasu-Hakola disease, which is characterized by central microglial pathology [60, 61].”
BackgroundTMEM59 interacts with TREM2 and modulates TREM2-dependent microglial activities
Liu, Z., Ning, J., Zheng, X., Meng, J., Han, L., Zheng, H., Zhong, L., Chen, X., Zhang, X., Luo, H., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02874-3 · Cited by 37
Amos, P. J., Fung, S., Case, A., Kifelew, J., Osnis, L., Smith, C. L., Green, K., Naydenov, A., Aloi, M., Hubbard, J. J., et al. (2017) · ASN Neuro · doi:10.1177/1759091417716610 · Cited by 33
“…the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). neurodegenerative diseases (Paloneva et al., 2000, 2002; Rademakers et al., 2012) or lead to increased risk of AD (Guerreiro et al., 2013; Jonsson et al., 2013).”
BackgroundEtxeberria, A., Shen, Y.-A. A., Vito, S., Silverman, S. M., Imperio, J., Lalehzadeh, G., Soung, A. L., Du, C., Xie, L., Choy, M. K., et al. (2024) · The Journal of Neuroscience · doi:10.1523/jneurosci.2347-23.2024 · Cited by 35
Konishi, H., & Kiyama, H. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104878 · Cited by 34
CELF2 regulates the species-specific alternative splicing of TREM2
Yanaizu, M., Washizu, C., Nukina, N., Satoh, J., & Kino, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-75057-x · Cited by 37
Cheng, B., Li, X., Dai, K., Duan, S., Rong, Z., Chen, Y., Lü, L., Liu, Z., Huang, X., Xu, H., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.633796 · Cited by 40
“However, the loss of functions in TREM2 in humans resulted in a severe form of dementia with bone cystic lesions known as Nasu-Hakola disease (NHD), a lethal form of progressive, early onset dementia (33).”
BackgroundLC3, an autophagosome marker, is expressed on oligodendrocytes in Nasu-Hakola disease brains
Satoh, J.-I., Motohashi, N., Kino, Y., Ishida, T., Yagishita, S., Jinnai, K., Arai, N., Nakamagoe, K., Tamaoka, A., Saito, Y., et al. (2014) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-9-68 · Cited by 34
“1 [5-7].”
TREM2+ macrophages: a key role in disease development
Wang, X., Wang, Y., Yang, L. X., Zhang, Y., & Yang, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1550893 · Cited by 43
Variant TREM2 Signaling in Alzheimer's Disease
Olufunmilayo, E. O., & Holsinger, R. M. D. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167470 · Cited by 34
Alzheimer’s Disease Treatment: The Search for a Breakthrough
Reiss, A. B., Muhieddine, D., Jacob, B., Mesbah, M., Pinkhasov, A., Gomolin, I. H., Stecker, M. M., Wısnıewskı, T., & Leon, J. D. (2023) · Medicina · doi:10.3390/medicina59061084 · Cited by 37
“Initially, TREM2 was studied after gene sequencing revealed that this receptor’s homozygous loss of function mutation led to an autosomal recessive disease known as Nasu-Hakola disease, which involves early-onset dementia and bone pathology [70].”
BackgroundMolecular Pathogenesis and Interventional Strategies for Alzheimer’s Disease: Promises and Pitfalls
Bhute, S., Sarmah, D., Datta, A., Rane, P., Shard, A., Goswami, A., Borah, A., Kalia, K., Dave, K. R., & Bhattacharya, P. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00104 · Cited by 34
TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy
Qiu, H., Shao, Z., Wen, X., Jiang, J., Ma, Q., Wang, Y., Huang, L., Ding, X., & Zhang, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.716710 · Cited by 32
“Of greater significance, several studies had detected sTREM2 in the biological fluids (for example, cerebrospinal fluid) of patients suffering from NasuHakola disease, multiple sclerosis and other inflammatory neurological diseases, and the level of sTREM2 was significantly related to disease severity (39, 40), indica…”
BackgroundThe role of TREM2 N-glycans in trafficking to the cell surface and signal transduction of TREM2
Shirotani, K., Hatta, D., Wakita, N., Watanabe, K., & Iwata, N. (2022) · The Journal of Biochemistry · doi:10.1093/jb/mvac073 · Cited by 33
Dual functions of microglia in the formation and refinement of neural circuits during development
Konishi, H., Kiyama, H., & Ueno, M. (2018) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2018.09.009 · Cited by 35
“For instance, as described in the pre- vious section, DAP12 and TREM2 are known as causative genes for Nasu-Hakola disease, an early-onset dementia (Paloneva et al., 2000, 2001, 2002).”
BackgroundSteiner, A., Schlepckow, K., Brunner, B., Steiner, H., Haass, C., & Hagn, F. (2020) · The EMBO Journal · doi:10.15252/embj.2019104247 · Cited by 33
“In TREM2, a lysine residue is located within the TMH and its homozygous mutation has been connected to various diseases, like Nasu-Hakola disease (Paloneva et al , 2002).”
BackgroundAdipoclast: a multinucleated fat-eating macrophage
Olona, A., Mukhopadhyay, S., Hateley, C., Martínez, F. O., Gordon, S., & Behmoaras, J. V. (2021) · BMC Biology · doi:10.1186/s12915-021-01181-3 · Cited by 33
“Furthermore, deletions or loss-of-function mutations in either DAP12 or TREM2 are causally associated with Nasu–Hakola disease, a dementia associated with bone cystic lesions [63, 64].”
BackgroundPattern recognition receptors and their involvement in the pathogenesis of arthritis
Seibl, R., Kyburz, D., Lauener, R. P., & Gay, S. (2004) · Current Opinion in Rheumatology · doi:10.1097/01.bor.0000127108.08398.34 · Cited by 32
CSF sTREM2 in neurological diseases: a two-sample Mendelian randomization study
Dong, M.-H., Zhou, L.-Q., Tang, Y., Chen, M., Xiao, J., Shang, K., Deng, G., Qin, C., & Tian, D.-S. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02443-9 · Cited by 31
“Triggering receptor expressed on myeloid cells 2 (TREM2) is a kind of cell surface transmembrane glycoprotein composed of 230 amino acids [30].”
BackgroundThe diverse roles of macrophages in metabolic inflammation and its resolution
Ray, A. G., Odum, O., Wiseman, D., & Weinstock, A. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1147434 · Cited by 34
“Subsequent studies also showed that Trem2 deficiency or loss of function impairs lipid metabolism leading to neuroinflammatory diseases (Paloneva et al., 2002).”
BackgroundErythromyeloid-Derived TREM2: A Major Determinant of Alzheimer’s Disease Pathology in Down Syndrome
Raha-Chowdhury, R., Henderson, J. W., Raha, A. A., Stott, S. R. W., Vuono, R., Foscarin, S., Wilson, L., Annus, T., Fincham, R., Allinson, K., et al. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170814 · Cited by 31
“Homozygosity of other mutations in TREM2 or DAP12 cause a rare form of dementia with bone abnormalities called Nasu-Hakola disease (or polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy) [18, 19].”
BackgroundSiglecs that Associate with DAP12
Angata, T. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-1580-4_9 · Cited by 32
Metadata
- Authors
- Paloneva, J., Manninen, T., Christman, G., Hovanes, K., Mandelin, J., Adolfsson, R., Bianchin, M., Bird, T., Miranda, R., Salmaggi, A., Tranebjærg, L., Konttinen, Y., & Peltonen, L.
- Affiliations
- University of Helsinki (FI)
- University of California, Los Angeles (US)
- Umeå University (SE)
- University of Washington (US)
- Hospital Universitario La Paz (ES)
- Fondazione IRCCS Istituto Neurologico Carlo Besta (IT)
- Bispebjerg Hospital (DK)
- Helsinki University Hospital (FI)
- Corresponding author
- Peltonen, Leena
- ORCID
- Venue
- The American Journal of Human Genetics
- Publisher
- Elsevier BV
- Published
- 2002-09
- Volume
- 71
- Issue
- 3
- Pages
- 656-662
- ISSN
- 0002-9297 (ISSN-L)
- PMC
- PMC379202
- OpenAlex
- W2014200126
- Cited by
- 683
- References
- 29
- Citations by year
- 2026: 28 · 2025: 32 · 2024: 27 · 2023: 35 · 2022: 37 · 2021: 48 · 2020: 47 · 2019: 34 · 2018: 54 · 2017: 53 · 2016: 38 · 2015: 42 · 2014: 29 · 2013: 28 · 2012: 11
- FWCI
- 6.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 3974 d)
- Locations
- The American Journal of Human Genetics (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Lastentautien Tutkimussäätiö
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Nasu-Hakola disease, TREM2, TYROBP, DAP12, receptor signaling complex, genetic heterogeneity, progressive dementia, bone cysts, recessive inheritance
- MeSH terms
- Triggering Receptor Expressed on Myeloid Cells-1, Actins, Female, Haplotypes, Humans, Male, Membrane Glycoproteins, Membrane Proteins, Molecular Sequence Data, Mutation, Pedigree, Phenotype, Receptors, Immunologic, RNA, Messenger, Signal Transduction, Reverse Transcriptase Polymerase Chain Reaction, Gene Expression Profiling, Protein Subunits, Macromolecular Substances, Adaptor Proteins, Signal Transducing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.